Bio-Connect

Mouse anti Human Sphingosine 1 Phosphate 4 Receptor (CT) (EDG6), conjugated with FITC

Research Use Only
X1626M
Nordic-MUbio
ApplicationsFlow Cytometry, Western Blot
Product group Antibodies
ReactivityHuman
€ 578,00
100 ug
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Nordic-MUbio
  • Product Name
    Mouse anti Human Sphingosine 1 Phosphate 4 Receptor (CT) (EDG6), conjugated with FITC
  • Delivery Days Customer
    7
  • Applications
    Flow Cytometry, Western Blot
  • Applications Supplier
    Western Blotting;Flow Cytometry
  • Category Supplier
    Primary antibodies
  • Certification
    Research Use Only
  • Clone ID
    1
  • Concentration
    See vial for concentration
  • Conjugate
    FITC
  • Host
    Mouse
  • Isotype
    IgG1
  • Scientific Description
    Endothelial cell differentiation gene 6 C-terminal; Sphingosine-1-Phosphate Receptor-4 (S1P4)
  • Shelf life instruction
    See expiration date on vial
  • Source
    Hybridoma produced by the fusion of splenocytes from mice immunized with a unique synthetic peptide derived from the C-terminal region of the EDG6 (S1P4) protein and mouse myeloma cells.
  • Reactivity
    Human
  • Reactivity Supplier
    Human
  • Storage Instruction
    Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles
  • UNSPSC
    12352203

References

  • 1. Yamazaki, Y., et al. 'EDG-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway.' Biochem. Biophys. Res. Commun. 2000, 268, 583-589. 2. Van Brocklyn, J.R., et al. 'Sphingosine 1-phosphate is a ligand for the G protein-coupled receptor EDG-6.' Blood 2000, 95, 2624-2629. 3. Takuwa, Y., et al. 'Subtype-specific, differential activities of the EDG family receptors for sphingosine 1-phosphate, a novel lysophospholipid mediator.' Mol. Cell Endocrinol. 2001, 177, 3-11. 4. Ohotski, J., et al. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br. J. Can. (2012), 106, 1453-1459